- Home
- NUVB vs SLQT Comparison
NUVB vs SLQT Comparison
Compare NUVB & SLQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- SLQT
- Stock Information
- Founded
- NUVB 2018
- SLQT 1999
- Country
- NUVB United States
- SLQT United States
- Employees
- NUVB N/A
- SLQT N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- SLQT Specialty Insurers
- Sector
- NUVB Health Care
- SLQT Finance
- Exchange
- NUVB Nasdaq
- SLQT Nasdaq
- Market Cap
- NUVB 1.1B
- SLQT 362.3M
- IPO Year
- NUVB N/A
- SLQT 2020
- Fundamental
- Price
- NUVB $4.83
- SLQT $2.05
- Analyst Decision
- NUVB Strong Buy
- SLQT Hold
- Analyst Count
- NUVB 7
- SLQT 2
- Target Price
- NUVB $8.43
- SLQT $4.38
- AVG Volume (30 Days)
- NUVB 8.0M
- SLQT 1.1M
- Earning Date
- NUVB 11-03-2025
- SLQT 11-06-2025
- Dividend Yield
- NUVB N/A
- SLQT N/A
- EPS Growth
- NUVB N/A
- SLQT N/A
- EPS
- NUVB N/A
- SLQT 0.01
- Revenue
- NUVB $14,355,000.00
- SLQT $1,526,594,000.00
- Revenue This Year
- NUVB $291.13
- SLQT $13.98
- Revenue Next Year
- NUVB $332.00
- SLQT $9.54
- P/E Ratio
- NUVB N/A
- SLQT $154.53
- Revenue Growth
- NUVB 900.35
- SLQT 15.50
- 52 Week Low
- NUVB $1.54
- SLQT $1.62
- 52 Week High
- NUVB $4.87
- SLQT $6.86
- Technical
- Relative Strength Index (RSI)
- NUVB 74.53
- SLQT 54.03
- Support Level
- NUVB $3.36
- SLQT $1.91
- Resistance Level
- NUVB $3.84
- SLQT $2.04
- Average True Range (ATR)
- NUVB 0.28
- SLQT 0.09
- MACD
- NUVB 0.08
- SLQT 0.01
- Stochastic Oscillator
- NUVB 96.98
- SLQT 79.63
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.